CD96 and chronic myelogenous leukemia, BCR-ABL1 positive: We showed that genetic ablation of CD96 in human T cells enabled these cells to kill chronic myeloid leukemia (CML) cells and a subset of acute myeloid leukemia (AML) cells more efficiently in vitro.